Skip to Content

Prevnar 20 FDA Approval History

Last updated by Judith Stewart, BPharm on June 14, 2021.

FDA Approved: Yes (First approved June 8, 2021)
Brand name: Prevnar 20
Generic name: pneumococcal 20-valent conjugate vaccine
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Pneumococcal Disease Prophylaxis

Prevnar 20 (pneumococcal 20-valent conjugate vaccine) is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.

Development Timeline for Prevnar 20

DateArticle
Jun  8, 2021Approval  FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.